Ming Wang
Company: Phanes Therapeutics Inc.
Job title: President & Chief Executive Officer
Seminars:
Panel Discussion – Selecting Combination Partners Rationally 11:30 am
What types of features should we look for in a potential combination partner for CD73/CD39 inhibitors? What can we identify as being a good partner for A2AR and A2B? Discuss a methodology that can be used as a process for assessing potential combination partners that improves patient responses and safety profiles Postulate what partners have…Read more
day: Day One